Pharma
Documentation Ring
(P-D-R)
Direction and what we
are trying to
accomplish
SLA PHTL Spring Meeting
11-13. April 2010
&
Henning P. Nielsen
what does it mean to
you?
1958
P-D-R = “Pharma Dokumentation Ring” was
founded by five companies in Germany:
Bayer, Ciba (Novartis), Knoll (Abbott),
Merck, Thomae (Boehringer Ingelheim)

Join forces to index
scientific biomedical literature
Agenda:
•
•
•
•
•
•
•
What is P-D-R?
Who are we?
How are we working?
What has been/are our main focus areas?
What have we achieved?
Impact on you?
Why is it working so well?
What is P-D-R? (P-D-R Scope and Guidelines: )
The association, which bears the name:
"Pharma Documentation Ring" (P‐D‐R)
is a corporate‐based
non‐profit making
organization.
Member organisations:
• Member organisations should be research-based
pharmaceutical, biotech, or chemical companies having
a research-based pharmaceutical division or subsidiary
• Membership is corporate‐based.
• A corporate group is represented by a single
membership of the P‐D‐R, affiliated or subsidiary
companies being covered by this membership.
• One rep per company
– second rep may be accepted depending on structure
What’s the costs?
• Membership fees are not exacted. !!
• Members must, however, commit to make a
positive contribution to the work of the P-D-R by
actively participating in meetings, working
groups, as well as acting as a coordinator of a PD-R topic.
• Members must also commit to host an AGM on a
rota basis.
Who are we?
P-D-R : 24 corporate members
from EU, US, AUS, and J
Wyeth
ABBOTT
ASTRAZENECA
UCB
BASF
TAKEDA
BAYER
HEALTHCARE
SOLVAY
SCHERING-PLOUGH
BOEHRINGER
INGELHEIM
SANOFI AVENTIS
PFIZER
BRISTOL-MYERS
SQUIBB
NYCOMED
CSL BEHRING
NOVO NORDISK
ELI LILLY
NOVARTIS
FERRING
MERCK & CO
GILEAD
MERCK KGaA
GLAXOSMITHKLINE
HOFFMANNLA ROCHE
Status: January 2010
How
do
we
work
?
Aims
Promote exchange of
experience and networking
among members
Jointly assess new
and existing products
and services
Provide a forum for
the information
industry
Encourage commercial
development of new information
services and systems
How do we work?
The organs of the association:
– P-D-R Executive Board
– Meeting of the members AGM
– Topic Group Teams
– Ad hoc task force groups
– Special Meetings
P-D-R
Executive Board
Claudia Körner - Bayer HealthCare
Lou Ann Di Nallo - BMS
Matthias Staab – Sanofi-Aventis
Henning Nielsen - Novo Nordisk
• Elected at the AGM for 2 years
• Prepares and runs the AGM
together with host company
• Selects strategic topics
• Allocates members to topic
groups
• Initiates special meetings
• Adapts scope and guidelines
to the needs
• First contact for providers and
potential new members
• And all the other things:
coaching, pushing, firefighting,
etc…
AGMs
• Host company on a rotating basis
• Attended by all member companies
•
•
•
•
Company reports
Topic sessions
1-2 strategic sessions
Contact with other organizations
Topic Groups:
• Each representative assigned to a topic
• Topic co-ordinator appointed
• Topics regularly reviewed for
appropriateness - is this still a hot topic?
• Presentations to AGM summing up the
main events in that topic area
– guest speakers
– survey results
Current Topic Groups
•
Biomedical
Information
•
Business
Information
•
Chemical
Information and
Patents
•
Information and
Knowledge
Management
•
Library Affairs and
Copyright
•
Technology &
Intranet/Internet
•
P-D-R News & Website
Ad-Hoc Task Forces &
Special meetings – examples
•
•
•
•
•
•
•
•
•
•
•
•
•
Inter/intranet -1997
Electronic journal licensing - 1998
Knowledge management - 1999
Linking – 2000
Biotechnology Information & Intellectual Property - 2002
Taxonomy & Text mining 2003
Taskforce on e-journals 2004
P-D-R / SSP meeting 2006
3rd party usage – 2006
Copyright 2005/06
PDR/STM on use of publications - 2008
Marketing use of publications – 2009
…
P-D-R surveys
• 28 surveys in 2009
• big and small
• only respondents
receive the
consolidated,
anonymised report
• many leading to
AGM reports
08/04/2015
18
Main focus areas:
• Building a global network of information
management groups within the
pharmaceutical sector – and creating the
atmosphere of sharing and exchange of
ideas
• Establishing P-D-R as a known association
and player in the information world &
creating an understanding of the special
needs of the pharma industry
Main focus areas:
• Partnering with the information
industry:
– Creating new model licenses and
guidelines
– Involving P-D-R members in advisory boards
– Involving P-D-R in experiments and developments
of new tools and technologies
• Partnering with other information
groups - as today
Achievements
Promote exchange
of experience and
networking among
members
• Concurrent
benchmarking
• Small member group
with the necessary
confidence to respect
the openness and
confidentiality of our
discussions
Achievements
Jointly assess new
and existing
products and
services
•Meetings with
stakeholders,
publishers, suppliers
•Collectively
addressing suppliers
with problems and
possible solutions
•Surveys
Achievements
Provide a
forum for the
information
industry
• Memberships of
advisory boards
• Presenting at
meetings,
conferences,…
• Attendance to our
special meetings
• Speak with one
voice
Encourage commercial development of new
information services and systems
• Ringdoc = Derwent Drug File
• Actively partner with suppliers in enhancement
and development of systems
• Textmining / ontology experimental task forces
Journal licensing and usage rights 12 years of partnering with publishers and their associations.
• P-D-R Spring Meeting On Electronic Journals May 1998
• P-D-R STM/ALPSP task force on e-journal licensing 19982000 / Draft Model Licence
• P-D-R Proposal for Quality Standards of Electronic STM
Journals. 2004
• Pharmaceutical Industry/Publishers’ Working Group
Guidelines for External Distribution of E-Content. 2004
Journal licensing and usage rights 12 years of partnering with publishers and their associations.
• PDR SSP meeting in Baltimore June 2006
• P-D-R Task Force on copyright 2006-2007: New Model
Licence for Publications in the Pharmaceutical Industry.
2007
• P-D-R stakeholder meeting in Montpellier on scholarly
publishing and pharma needs. February 2008.
• PDR/STM stakeholder meeting in Reims on marketing
usage of scholarly publications. March 2009.
• Planning started on follow-up in 2011
What is the impact on you?
• Understanding of
your needs
among
stakeholders
• Impact on
information
resources and
developments
• Better licensing
terms
• …
Better licensing terms:
•
•
•
•
•
•
•
•
•
Model license
Definition of authorised users
Regulatory and patent litigation usage
Training purposes
Project storage
Medical information (unsolicited)
Scientific advisors
Scolarly sharing
Contractors
And we are working
on identifying the
gaps:
–
–
–
–
–
Outsourcing
Marketing usage
Translations
Our own content
Business models for
marketing usage
– Meeting 2011 (?)
Why is it working so well?
• Willingness to share - give and take within
the bounds of confidentiality and
competitive advantage
• Commitment makes things happen
• The best benchmarking tool we have
• Relatively small meetings - easy to
network
• The partnership approach to stakeholders
P-D-R in the last 15 years
• Shaped in the 90’s and matured in the new millennium
•23 companies working together on
learning, sharing, and impacting the information and
knowledge environment in the pharmaceutical industry
Partnering with the information industry to innovate,
develop, and promote the data and tools needed for our
corporate strategies
Being innovative in our use of new technologies
Being ready for changes affecting our contributions to
our corporate strategies
•Probably a rather unique association in a competitive world!!
And it is also a lot of fun!
Thank you for your attention!
Any questions?
References:
• Website: www.p-d-r.com
• Publications: www.p-d-r.com/publications/publications.html
• Latest article: Henning P.Nielsen and Sven-Olaf Vogt
• What pharmaceutical libraries really want.
• Learned Publishing. Vol.23 No.1 January 2010. 53-58.